再生不良性貧血の世界市場

再生不良性貧血の世界市場は2030年までに83億米ドルに達する見込み

2024年に68億米ドルと推定される再生不良性貧血の世界市場は、2024年から2030年にかけてCAGR 3.4％で成長し、2030年には83億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである後天性再生不良性貧血は、CAGR 4.0％を記録し、分析期間終了までに59億米ドルに達すると予測されます。継承された再生不良性貧血分野の成長率は、分析期間中CAGR 1.9％と推定されます。

米国市場は18億米ドルと推定、中国はCAGR 6.4％で成長予測

米国の再生不良性貧血市場は、2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3％と2.6％と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の再生不良性貧血市場- 主要動向と促進要因のまとめ

再生不良性貧血が希少疾患治療薬で再び注目される理由とは？

再生不良性貧血は、汎血球減少と骨髄細胞減少を特徴とする希少かつ生命を脅かす骨髄不全疾患であるが、診断の進歩、血液専門医の意識の高まり、標的治療薬のパイプラインの拡大により、世界のヘルスケアエコシステムにおいて注目が高まっています。この疾患は後天性または遺伝性で、赤血球、白血球、血小板の欠乏を引き起こし、重篤な疲労、感染症、出血性合併症を引き起こします。歴史的には、広範な免疫抑制剤と骨髄移植によって管理されてきたが、治療選択肢はドナーの入手可能性、再発リスク、長期毒性によって制限されていました。しかし、病態の分子生物学的解明、特に免疫による骨髄抑制とテロメア生物学の役割の解明が進み、造血を促進し、免疫異常を軽減し、生存率を向上させることを目的とした新規治療戦略の開発が進められています。

再生不良性貧血がより広範な骨髄不全症候群の一部として認識されるようになったことで、専門医療センター、早期スクリーニングプロトコル、精密医療アプローチへの投資が活発化しています。希少疾病用医薬品の指定や希少疾病の払い戻しを支援する規制の枠組みは、この分野における製薬研究をさらに後押ししています。再生不良性貧血の患者は、発作性夜間ヘモグロビン尿症（PNH）や骨髄異形成症候群（MDS）と重複した特徴を示すことが多いため、個別化治療を可能にする包括的診断とリスク層別化が重視されるようになっています。アンメット・クリニカル・ニーズは依然として高く、難治性または再発症例における生存期間は依然として最適とは言えないため、再生不良性貧血は希少血液疾患ポートフォリオの中で優先的に注目される領域として着実に浮上しています。

治療上のイノベーションと移植戦略は治療成績をどのように前進させているか？

再生不良性貧血における治療の進歩は、従来の免疫抑制療法（IST）にとどまらず、新規薬剤や併用レジメンによって奏効率や血液学的回復が改善されつつあります。抗胸腺細胞グロブリン（ATG）とシクロスポリンA（CsA）からなる標準的な第一選択ISTは、特に幹細胞移植不適格患者に対して広く使用されています。しかし、トロンボポエチン受容体作動薬であるエルトロンボパグを追加することで、多系統の造血が促進され、治療未治療患者と難治性患者の両方で全奏効が改善され、治療成績が著しく向上しました。この3剤併用プロトコールは現在、いくつかのガイドラインにおいて、特にマッチした兄弟姉妹ドナーがいない成人患者に対する新しい標準治療とみなされています。

治癒を目指す場合、造血幹細胞移植（HSCT）は、適合するドナーがいる若年で重症の再生不良性貧血患者に対するゴールドスタンダードであり続けています。コンディショニングレジメン、移植片対宿主病（GVHD）予防、ハプロアイデンティカル移植における革新は、ドナープールを拡大し、移植後の合併症を減少させています。テロメラーゼ活性化剤、標的補体阻害剤（PNHが重複している場合）、免疫チェックポイント調節の調査も勢いを増しています。再生不良性貧血の表現型を模倣した遺伝性骨髄不全症候群に対しては、遺伝子治療が予備的に検討されています。これらの治療イノベーションは、有効性、毒性、QOLのバランスをとりながら、より幅広い患者集団における持続的寛解と治癒に近づきつつある、治療に対するより微妙な、ステージに適応したアプローチを強化しつつあります。

再生不良性貧血治療の需要が伸びている地域と臨床の進展が見られる地域は？

再生不良性貧血治療に対する世界の需要は、北米、欧州、アジア太平洋地域で拡大しており、治療へのアクセス、ドナーの利用可能性、診断能力などが地域ごとの市場ダイナミクスに影響を及ぼしています。米国と西欧は臨床研究の最前線にあり、高度な移植インフラ、エルトロンボパグベースのレジメンの普及、臨床試験による実験的治療へのアクセスがあります。これらの地域の3次医療センターや学術機関も、実臨床でのエビデンス収集やプロトコールの最適化を促進する共同登録や希少疾患ネットワークを主導しています。

中国、インド、日本を中心とするアジア太平洋地域では、疾患有病率の上昇、ヘルスケアアクセスの改善、希少疾患プログラムに対する政府の支援により、診断と治療が大きく成長しています。特に中国には多くの患者プールがあり、IST製剤、幹細胞治療薬、トロンボポエチン作動薬の現地生産を増やして需要の増加に対応しています。インドでは、ドナー登録の限界は残るもの、費用対効果の高いISTレジメンと移植能力の拡大により、小児と成人の両コホートにおける転帰が改善されつつあります。ラテンアメリカと中東の新興市場では、国際援助、血液学プログラムの一元化、世界ヘルス組織との提携を通じて、診断スケジュールと治療の公平性が徐々に改善されつつあります。どの地域でも、認知度の向上と集学的治療モデルにより、患者の紹介、フォローアップ、救命治療へのアクセスが改善されつつあります。

再生不良性貧血市場の世界的成長の原動力は？

再生不良性貧血市場の成長は、免疫療法や幹細胞生物学の進歩、治療アクセスの拡大、希少疾患に対する支持的な政策枠組みなど、いくつかの要因によって牽引されています。主要な促進要因は、血液学的回復を改善し、早期死亡率を低下させる併用療法、特にISTを用いたエルトロンボパグの出現です。希少疾病用医薬品（オーファンドラッグ）や画期的治療薬（ブレークスルーセラピー）などの規制指定により、新規薬剤の開発と承認が加速しています。血液学的研究、精密診断、ドナー登録インフラへの投資の増加も、治療経路と移植準備の強化につながっています。

医薬品の技術革新は、産学連携、世界な患者登録、治療法選択のデータ駆動型改善を可能にする転帰追跡システムによってさらに支えられています。長期フォローアップ、服薬アドヒアランス、細胞減少症の遠隔モニタリングの管理におけるデジタルヘルスの役割の高まりは、慢性管理におけるケアの継続性を高めています。一般向けの啓発キャンペーンや希少疾患のアドボカシーは、診断の遅れを減らし、ヘルスケア提供者の関与を向上させるのに役立っています。治療法の選択肢が多様化し、生存率が向上する中、この市場の将来的な軌跡を形作る重要な疑問が浮上しています。再生不良性貧血ケアは、ドナーに依存した反応的なモデルから、個別化された血液学的回復を目標とする、誰もがアクセス可能なパラダイムへと進化することができるのだろうか？

セグメント

疾患タイプ（後天性再生不良性貧血、遺伝性再生不良性貧血）、治療タイプ（骨髄輸血、輸血、薬物療法）、投与方法（注射、経口、その他の投与方法）、エンドユーザー（病院、専門クリニック、その他のエンドユーザー）

調査対象企業の例（注目の43社）

• AbbVie Inc.
• Amgen Inc.
• Amyndas Pharmaceuticals S.A.
• Bayer AG
• BioLineRx Ltd.
• Bluebird Bio, Inc.
• Bristol-Myers Squibb Company
• Cadila Healthcare Limited（Zydus）
• Cellenkos Inc.
• CSL Limited
• Eisai Co., Ltd.
• Elixirgen Therapeutics, LLC
• F. Hoffmann-La Roche Ltd.
• Foresee Pharmaceuticals Co., Ltd.
• Gamida Cell Ltd.
• GlaxoSmithKline plc
• Hangzhou Zede Pharmaceutical Tech.
• Hemogenyx Pharmaceuticals plc
• Johnson & Johnson
• Kyowa Kirin Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Aplastic Anemia Market to Reach US$8.3 Billion by 2030

The global market for Aplastic Anemia estimated at US$6.8 Billion in the year 2024, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Acquired Aplastic Anemia, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$5.9 Billion by the end of the analysis period. Growth in the Inherited Aplastic Anemia segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 6.4% CAGR

The Aplastic Anemia market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Aplastic Anemia Market - Key Trends & Drivers Summarized

Why Is Aplastic Anemia Receiving Renewed Focus in Rare Disease Therapeutics?

Aplastic anemia-a rare and life-threatening bone marrow failure disorder characterized by pancytopenia and hypocellular marrow-is drawing increasing attention in the global healthcare ecosystem due to advances in diagnosis, growing awareness among hematologists, and the expanding pipeline of targeted therapies. The disease, which can be acquired or inherited, leads to a deficiency in red cells, white cells, and platelets, resulting in severe fatigue, infections, and bleeding complications. Historically managed with broad-spectrum immunosuppressants and bone marrow transplantation, treatment options were limited by donor availability, relapse risk, and long-term toxicity. However, improved molecular understanding of pathogenesis-especially the role of immune-mediated marrow suppression and telomere biology-is driving development of novel therapeutic strategies that aim to enhance hematopoiesis, reduce immune dysregulation, and improve survival rates.

The increasing recognition of aplastic anemia as part of the broader spectrum of bone marrow failure syndromes is prompting greater investment in specialized care centers, early screening protocols, and precision medicine approaches. Regulatory frameworks supporting orphan drug designations and rare disease reimbursement are further incentivizing pharmaceutical research in this space. As patients with aplastic anemia often present with overlapping features of paroxysmal nocturnal hemoglobinuria (PNH) or myelodysplastic syndromes (MDS), there is growing emphasis on comprehensive diagnostics and risk stratification to enable individualized therapy. With unmet clinical needs remaining high and survival still suboptimal in refractory or relapsed cases, aplastic anemia is steadily emerging as a priority focus area within rare hematology portfolios.

How Are Therapeutic Innovations and Transplant Strategies Advancing Treatment Outcomes?

Therapeutic advancements in aplastic anemia are expanding beyond traditional immunosuppressive therapy (IST), with novel agents and combination regimens showing improved response rates and hematologic recovery. The standard first-line IST-comprising antithymocyte globulin (ATG) and cyclosporine A (CsA)-continues to be widely used, particularly for patients ineligible for stem cell transplantation. However, the addition of eltrombopag, a thrombopoietin receptor agonist, has significantly enhanced outcomes by stimulating multilineage hematopoiesis and improving overall response in both treatment-naive and refractory patients. This triple-drug protocol is now considered a new standard of care in several guidelines, particularly for adult patients lacking matched sibling donors.

In the curative setting, hematopoietic stem cell transplantation (HSCT) remains the gold standard for young, severe aplastic anemia patients with compatible donors. Innovations in conditioning regimens, graft-versus-host disease (GVHD) prophylaxis, and haploidentical transplantation are expanding the donor pool and reducing post-transplant complications. Research into telomerase activators, targeted complement inhibitors (in cases with overlapping PNH), and immune checkpoint modulation is also gaining momentum. Gene therapy is under preliminary exploration for inherited bone marrow failure syndromes that mimic aplastic anemia phenotypes. These therapeutic innovations are reinforcing a more nuanced, stage-adapted approach to treatment-balancing efficacy, toxicity, and quality of life-while moving closer to durable remission and cure in broader patient populations.

Where Is Demand for Aplastic Anemia Treatment Growing and Which Regions Are Seeing Clinical Progress?

Global demand for aplastic anemia treatment is expanding across North America, Europe, and Asia-Pacific, with variations in treatment access, donor availability, and diagnostic capabilities influencing regional market dynamics. The United States and Western Europe are at the forefront of clinical research, with advanced transplant infrastructure, greater uptake of eltrombopag-based regimens, and access to experimental therapies through clinical trials. Tertiary care centers and academic institutions in these regions are also leading collaborative registries and rare disease networks that facilitate real-world evidence collection and protocol optimization.

Asia-Pacific-particularly China, India, and Japan-is witnessing significant growth in diagnosis and treatment due to higher disease prevalence, improved healthcare access, and government support for rare disease programs. China, in particular, has a large pool of aplastic anemia patients and is increasing local production of IST agents, stem cell therapies, and thrombopoietin agonists to meet growing demand. In India, while donor registry limitations persist, cost-effective IST regimens and expanding transplant capacity are improving outcomes in both pediatric and adult cohorts. Emerging markets in Latin America and the Middle East are gradually improving diagnostic timelines and treatment equity through international aid, centralized hematology programs, and partnerships with global health organizations. Across all regions, rising awareness and multidisciplinary care models are improving patient referral, follow-up, and access to lifesaving therapies.

What Is Driving the Global Growth of the Aplastic Anemia Therapeutics Market?

The growth in the aplastic anemia market is driven by several factors, including advances in immunotherapy and stem cell biology, expanding treatment access, and supportive policy frameworks for rare diseases. A key growth driver is the emergence of combination therapy approaches-particularly eltrombopag with IST-which are improving hematologic recovery and reducing early mortality. Regulatory designations such as orphan drug and breakthrough therapy status are expediting the development and approval of novel agents. Increased investment in hematologic research, precision diagnostics, and donor registry infrastructure is also strengthening treatment pathways and transplant readiness.

Pharmaceutical innovation is being further supported by academic-industry collaborations, global patient registries, and outcome tracking systems that enable data-driven improvements in therapy selection. The growing role of digital health in managing long-term follow-up, medication adherence, and telemonitoring of cytopenias is enhancing continuity of care in chronic management. Public awareness campaigns and rare disease advocacy are helping reduce diagnostic delays and improve healthcare provider engagement. As therapeutic options diversify and survival improves, a critical question now shapes the future trajectory of this market: Can aplastic anemia care evolve from a reactive, donor-dependent model into a targeted, universally accessible paradigm of personalized hematologic restoration?

SCOPE OF STUDY:

The report analyzes the Aplastic Anemia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Acquired Aplastic Anemia, Inherited Aplastic Anemia); Treatment Type (Bone Marrow Transfusion, Blood Transfusion, Drug Therapy); Mode of Administration (Injectable, Oral, Other Mode of Administrations); End-Use (Hospitals, Specialty Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Amyndas Pharmaceuticals S.A.
• Bayer AG
• BioLineRx Ltd.
• Bluebird Bio, Inc.
• Bristol-Myers Squibb Company
• Cadila Healthcare Limited (Zydus)
• Cellenkos Inc.
• CSL Limited
• Eisai Co., Ltd.
• Elixirgen Therapeutics, LLC
• F. Hoffmann-La Roche Ltd.
• Foresee Pharmaceuticals Co., Ltd.
• Gamida Cell Ltd.
• GlaxoSmithKline plc
• Hangzhou Zede Pharmaceutical Tech.
• Hemogenyx Pharmaceuticals plc
• Johnson & Johnson
• Kyowa Kirin Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Aplastic Anemia - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advances in Immunosuppressive Therapy Expand Treatment Options for Aplastic Anemia Patients
  • Stem Cell Transplant Innovations Improve Survival Outcomes in Severe Aplastic Anemia Cases
  • Growing Diagnostic Accuracy Enables Early-Stage Identification of Aplastic Anemia
  • Orphan Drug Designation Spurs R&D Investment in Novel Aplastic Anemia Therapies
  • Awareness Among Hematologists Drives Uptake of Protocol-Based Aplastic Anemia Treatments
  • Supportive Care Advancements Improve Quality of Life for Aplastic Anemia Patients
  • Rising Use of Eltrombopag and Growth Factors Enhances Treatment Personalization
  • Collaborative Research Consortia Strengthen Clinical Understanding of Aplastic Anemia Mechanisms
  • Health System Readiness in Emerging Markets Expands Access to Critical Aplastic Anemia Therapies
  • Hematopoietic Cell Registry Networks Support Efficient Donor-Recipient Matching for Transplants
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Aplastic Anemia Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acquired Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acquired Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Acquired Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Inherited Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Inherited Aplastic Anemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Inherited Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Bone Marrow Transfusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Bone Marrow Transfusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Bone Marrow Transfusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Blood Transfusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Blood Transfusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Blood Transfusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Mode of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Mode of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Mode of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• JAPAN
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• CHINA
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• EUROPE
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Aplastic Anemia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Aplastic Anemia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• FRANCE
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• GERMANY
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 137: UK Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Aplastic Anemia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• INDIA
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 212: India Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Aplastic Anemia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Aplastic Anemia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Aplastic Anemia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030
• AFRICA
  • Aplastic Anemia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Aplastic Anemia by Disease Type - Acquired Aplastic Anemia and Inherited Aplastic Anemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Aplastic Anemia by Disease Type - Percentage Breakdown of Value Sales for Acquired Aplastic Anemia and Inherited Aplastic Anemia for the Years 2015, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Aplastic Anemia by End-Use - Specialty Clinics, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Aplastic Anemia by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Aplastic Anemia by Treatment Type - Bone Marrow Transfusion, Blood Transfusion and Drug Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Aplastic Anemia by Treatment Type - Percentage Breakdown of Value Sales for Bone Marrow Transfusion, Blood Transfusion and Drug Therapy for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Aplastic Anemia by Mode of Administration - Injectable, Oral and Other Mode of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Aplastic Anemia by Mode of Administration - Percentage Breakdown of Value Sales for Injectable, Oral and Other Mode of Administrations for the Years 2015, 2025 & 2030

IV. COMPETITION